Serum Glycan Analysis in Breast Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- University of California, Davis
- Enrollment
- 163
- Locations
- 1
- Primary Endpoint
- Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer.
Detailed Description
OBJECTIVES: * To profile serum glycan biomarkers in women with metastatic stage IV breast cancer, healthy controls, and patients with noncancer medical illness. * To determine whether serial serum glycan biomarkers correlate with response of metastatic disease to treatment. OUTLINE: This is a multicenter study. Blood is collected from patients with metastatic breast cancer, patients with noncancerous illness, and healthy volunteers. Samples are analyzed for serum glycan biomarkers by matrix-assisted laser desorption/ionization (MALDI) and Fourier transform ion-cyclotron resonance mass spectrometry (FT ICR MS) methods. Blood samples are collected every 3 months for up to 18 months from patients with metastatic breast cancer. Patients without cancer have a single sample collected.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness
Time Frame: up to 18 months
Secondary Outcomes
- Predictability of serial serum biomarkers in determining disease response and/or progression(Up to 18 months)